Life Science Companies in United Kingdom (UK)

TEK Optima Research is a leading provider of advanced imaging systems and AI-powered software solutions, based in Wimborne, Dorset, UK.

We specialize in designing and manufacturing high-performance hardware and innovative DeepInsight cell fingerprinting technology for the Biotech, Medical, and related microscopic imaging industries. Our solutions enable faster, more accurate results for researchers and clinicians.

TEK Optima Research combines cutting-edge hardware development with sophisticated data analytics and AI to deliver a complete imaging platform. We support a wide range of applications, from drug discovery to clinical diagnostics.

Founded in 2019, we’ve quickly established ourselves as a trusted partner for organizations seeking to push the boundaries of microscopic imaging. We currently employ a team of 5 dedicated professionals, operating from our R&D office and manufacturing facility in Dorset and a secondary R&D office in Durham, NC.

Genomics is a pioneering transatlantic TechBio company based in Oxford, UK, specializing in **genomic prevention** and transforming healthcare through the power of genomics.

We leverage large-scale genetic information to provide accurate, personalized risk estimates for common diseases and cancers, enabling early interventions and tailored screening. Our proprietary algorithms and databases link minute variations across the entire genome to biological measurements and disease outcomes, generating population-level insights for healthcare systems and individual-level risk assessments for clinicians.

Genomics partners with leading life sciences and biotech companies, including Novo Nordisk and Vertex, offering a unique approach to sustainable healthcare. Our team of over 150 experts – including world-leading genomic scientists, computational biologists, and data scientists – is dedicated to bringing subject-leading science to a global audience, ultimately transforming lives.

BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report. We specialise in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.

At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

Automata was founded with a clear aim: to unlock human potential with automation. Through our collaboration with some of the world’s leading pathology labs, we’ve developed the most comprehensive lab automation platform on the market. By simplifying environments and empowering people, Automata enables labs to scale with precision and creates new opportunities for scientists to accelerate innovation.

Biorelate helps scientists solving the most difficult biomedical challenges of today. We do this by curating truths from existing knowledge, enabling smarter and faster research & development.

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry. C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m. The Company was founded as a spin-out from the University of Manchester. t has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. Website: www.c4xdiscovery.com Twitter: @C4XDiscovery

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised, allowing our customers to understand the machinery of life. We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit. Twitter: @fluidicanalytic

Imagen Therapeutics is a biotech company based in the UK, with an ongoing commitment to improving the outcomes of cancer patients by accelerating drug discovery and the development of new cancer therapies. Our main activities include offering personalised clinical diagnostic services to cancer patients, offering contract research services, and developing a world-leading well-characterised Biobank.

Metrion Biosciences is a UK-based Contract Research Organization specialising in high quality ion channel screening and drug development expertise. We aim to provide our customers with access to a range of in vitro screening services that includes cardiac safety (hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, our management team have amassed over 80 years of experience in ion channel drug discovery and our clients can access this high level of expertise as part of our dedicated service.

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

Nuclera is making biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day. Biological research and drug discovery projects begin with and rely on proteins. However, using traditional methods to obtain proteins of interest can take up to 6 months and often include many trials and failures. What if there was an easier way? At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

See protein, DNA and RNA molecules that make life work, in nanoparticles, viruses, bacteria, cells and tissue. We believe that understanding science at a molecular level will fundamentally allow you to unlock new discoveries, so we created our flagship product, The Nanoimager. We built the world's first desktop compatible compact super-resolution microscope, but we did it our way. Our teams have a restless enthusiasm to bring technologies like super-resolution to a new community of researchers and we continue working until barriers of accessibility and affordability are addressed. Our mission is to ensure research and collaboration tools are available to those willing to ask why or how things are the way they are and answer questions never asked before. We can’t wait to see and hear about what new questions you will ask!

Harnessing the power of deep learning on 3D molecular configurations to deliver medicines of transformational efficacy to patients.

At Biomage, we are deeply passionate about the goal of improving human health. We are achieving this goal by creating a single cell analytics platform, Cellscope, which empowers researchers to gain unprecedented insight into complex datasets, discover new drug targets and answer deep biological questions. We take away technical difficulties and bring clarity to 'big data' using accessible and intuitive tools. Cellscope enables the research biologist to analyse their datasets without the need for bioinformatics expertise. Its user friendly interface and intuitive software empowers researchers to take ownership of their single cell analysis, generating biological insight in just a few clicks. * For academic users it's free - sign up at https://www.biomage.net/signup * If you’re looking to become an industry partner, visit https://www.biomage.net/partnerships or reach out to our CEO: Adam@biomage.net Discover. One cell at a time.

EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

CardiaTec is applying artificial intelligence on large-scale human multi-omics data to develop the next generation of cardiovascular disease drug targets.

Our mission at MiroBio is to deliver transformational immunotherapies for people suffering from autoimmune disease. Immune imbalance is at the heart of many conditions which are marked by an attack on the body’s own cells. MiroBio is advancing a new class of therapies designed to restore immune balance – or homeostasis – and potentially provide durable remission from these chronic, complex conditions. To achieve this, MiroBio has built deep expertise in an emerging area of immunology: precise activation of inhibitory pathways to restore healthy immune function. Our pipeline of agonistic antibodies and supporting platform are informed by over a decade of foundational research. MiroBio draws upon a transatlantic team of advisers, drug developers and leading healthcare investors to further its leadership in this vast new area of immunology.

Osler is a UK-based diagnostics company whose purpose is to enable anyone, anywhere, to access, understand, and act on their health, to live healthier, happier, and longer lives. Osler has developed the Osler Origin – a 'portable lab' that can provide lab-quality diagnostics to anyone, anywhere, at any time. The Osler Origin will offer a wide portfolio of diagnostic tests and serve all major healthcare settings, globally. Osler was formed out of the University of Oxford in 2017, following decades of research from the same department that invented the portable electrochemical blood glucose sensor. The Company is headquartered in Oxford, UK.

LIYSF (London International Youth Science Forum) is a 14-day immersive STEM Summer School for students aged 16-21 hosted at Imperial College London. Founded in 1959, it brings together 500 students from 90 countries under the Royal Patronage of HRH The Princess Royal. The program offers pre-university exposure to real-world research, interaction with Nobel Prize winners and leading scientists, and deep dives into the latest STEM innovations.